SignaCor

Based in the United Kingdom, SignaCor is a startup. Its most recent tracked round is Seed. Brouky classifies it under Healthcare & Life Sciences. Brouky records 1 investor associated with the company.

SignaCor is a clinical-stage biotech company developing Cardiaza, a first-in-class epigenetic modifying therapy that targets the underlying disease pathology of symptomatic hypertrophic cardiomyopathy (HCM) by modifying DNA methylation to reduce fibrosis, hypertrophy, inflammation, and improve cardiac function.